Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.
about
Molecular Subtypes and Personalized Therapy in Metastatic Colorectal CancerImplications of mismatch repair-deficient status on management of early stage colorectal cancerMolecular phenotypes of colorectal cancer and potential clinical applicationsDifferent treatment strategies and molecular features between right-sided and left-sided colon cancersGenomic Profiling in Gastrointestinal Cancer: Are We Ready To Use These Data to Make Treatment Decisions?DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic studyKRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).Prognostic and predictive significance of MSI in stages II/III colon cancer.The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients.Screening for mismatch repair deficiency in colorectal cancer: data from three academic medical centers.Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147Tumor LINE-1 methylation level and microsatellite instability in relation to colorectal cancer prognosis.Prognostic Impact of Deficient DNA Mismatch Repair and Mutations in KRAS, and BRAF(V600E) in Patients with Lymph Node-Positive Colon CancerMolecular markers identify subtypes of stage III colon cancer associated with patient outcomesThe significance of combining VEGFA, FLT1, and KDR expressions in colon cancer patient prognosis and predicting response to bevacizumabRandomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stageDistinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations.Molecular markers predictive of chemotherapy response in colorectal cancerDistinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy.Microsatellite instability testing and its role in the management of colorectal cancer.Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance)Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal CancerPrognostic impact of mutation profiling in patients with stage II and III colon cancerHereditary cancer syndromes: utilizing DNA repair deficiency as therapeutic targetSessile Serrated Polyps are Precursors of Colon Carcinomas With Deficient DNA Mismatch Repair.Prognostic and predictive value of extended RAS mutation and mismatch repair status in stage III colorectal cancerClinical course and outcome of patients with high-level microsatellite instability cancers in a real-life setting: a retrospective analysis.Genetics, biomarkers, hereditary cancer syndrome diagnosis, heterogeneity and treatment: a review.Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial.Prognostic and Predictive Biomarkers in Colorectal Cancer: Implications for the Clinical Surgeon.Precision medicine in colorectal cancer: evolving genomic landscape and emerging consensus.Expending Role of Microsatellite Instability in Diagnosis and Treatment of Colorectal Cancers.Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications.Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer.Cancer predisposition syndromes: lessons for truly precision medicine.The prognostic implications of primary colorectal tumor location on recurrence and overall survival in patients undergoing resection for colorectal liver metastasis.What We Know About Stage II and III Colon Cancer: It's Still Not Enough.
P2860
Q26747329-842E3512-D531-4B2F-B8DE-BCBE18A3613DQ26772272-DB1125B4-A13C-493D-AF35-E3AE0ACF54B6Q26785725-4E630619-4ABD-4542-BBF5-AB6217C02B0BQ26865322-FE9FCA09-D164-4BB4-A63D-580BDC51C99FQ31012680-606362DB-34EC-4C37-9CB8-10FD13A1FDD2Q33418614-A555B13B-4B80-4DA5-8B6B-143A4D00680BQ33682949-210703A2-8CDE-4540-AF69-45701CD73374Q33693309-B2F82D69-562C-457A-8332-2E183CA5A910Q33735239-BC3E2DBE-6BEB-4253-901B-D07ED999EF3AQ33768220-4AAA777D-C657-4AA7-A41A-518FE5EFFA39Q33775296-34B3EC74-144E-4346-AD09-A7D140AC966FQ33855053-45FAB88C-5612-4399-9BA6-02ECC1629544Q33947880-84E034F2-D933-43EC-BC1E-EADDEE9D26D5Q34169734-6B476E19-041A-4FBD-BAAF-C744D4D3066FQ34472453-7D3E24E4-77BD-4067-BB33-EE9A680BD813Q34665492-318BD146-93A2-491B-83B8-8AA42BCE616AQ35491379-1C4D80A1-EC11-4CDA-ACCA-645367B057EEQ35625752-6B750BA0-0C5D-4BFE-80B7-F905B83042E8Q35652713-C453006F-AFE3-4DB8-B7E7-2E16368F099DQ35761956-1DB494B5-868A-4E4C-ACBC-06ADA8B5D4AAQ35773077-508348C0-644B-4B0A-9EA2-AA089F8444A5Q36124008-95E08FB6-33A5-45F8-989C-7775B9AEE341Q36342900-C6915907-52F2-43B7-8C58-A9B3F94F2359Q36558421-1EC64EED-9CD2-477B-BE3C-0ADD684D3676Q36796320-E0EA007B-869F-45FC-A373-7584F486AF66Q36990060-39ED1B87-5489-462B-91F3-72CD577C7C70Q37018440-AE61CDEF-4CE9-4B5D-A6CF-E335C8C04DBBQ37098312-B24C4FBE-EB60-4180-AF61-3E0487854A9DQ37741987-86CC7C9F-4D07-4382-AD0D-F39288F15E7FQ38211737-28765D2E-7C00-4848-A08B-5CD9DEAC3185Q38383214-1F3A7E42-D090-42CF-9AAB-D284DF2E3B99Q38421451-BDD42E18-BEEF-42C0-9D1C-0B9C5028AC76Q38555225-FF99F11E-2900-44DA-A175-87B1749ACB05Q38580566-80571218-DF85-4B7D-8815-3F28C9470B25Q38683093-9AFC6245-A301-42CC-BD1B-25F1E22BBEE3Q38794338-2C5C3AE8-4767-41FC-B18D-6D9079F182C9Q38868401-07F1AB5B-092D-4F52-B362-EE138BEA3A70Q39012229-FAB72F39-FCA9-4A36-A7CF-26444221D427Q39238657-543A5CF0-FB0C-4D1B-9741-D0E093B1DB14Q39306576-9E3D31D2-CC90-4560-B5D0-141B37C3D274
P2860
Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Prognostic impact of deficient ...... X-based adjuvant chemotherapy.
@ast
Prognostic impact of deficient ...... X-based adjuvant chemotherapy.
@en
Prognostic impact of deficient ...... X-based adjuvant chemotherapy.
@nl
type
label
Prognostic impact of deficient ...... X-based adjuvant chemotherapy.
@ast
Prognostic impact of deficient ...... X-based adjuvant chemotherapy.
@en
Prognostic impact of deficient ...... X-based adjuvant chemotherapy.
@nl
prefLabel
Prognostic impact of deficient ...... X-based adjuvant chemotherapy.
@ast
Prognostic impact of deficient ...... X-based adjuvant chemotherapy.
@en
Prognostic impact of deficient ...... X-based adjuvant chemotherapy.
@nl
P2093
P2860
P356
P1476
Prognostic impact of deficient ...... X-based adjuvant chemotherapy.
@en
P2093
Daniel J Sargent
Frank A Sinicrope
Garth D Nelson
Michelle R Mahoney
Monica M Bertagnolli
Richard M Goldberg
Robert S Warren
Stephen N Thibodeau
Steven R Alberts
P2860
P304
P356
10.1200/JCO.2013.48.9591
P407
P577
2013-09-09T00:00:00Z